Cargando…
Renal targeted protein therapeutics in experimental overt heart failure with renal dysfunction
Autores principales: | Chen, Horng H, Cataliotti, Alessandro, Martin, Fernando L, Schirger, John A, Burnett, John C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313385/ http://dx.doi.org/10.1186/1471-2210-9-S1-P7 |
Ejemplares similares
-
M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
por: McKie, Paul M, et al.
Publicado: (2013) -
The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation
por: Schirger, John A, et al.
Publicado: (2009) -
The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011) -
Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
por: Boerrigter, Guido, et al.
Publicado: (2011) -
Chronic natriuretic peptide protein therapeutics
por: Chen, Horng H, et al.
Publicado: (2013)